GlassScriptPhysician profile
Amanda M Rubin
NPI 1588235626
$1,209.09
in general payments reported to CMS, 2019-2025
17 companies · $128 in 2025
The $128 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $113 · 2023: $479 · 2024: $489 · 2025: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,096.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,095.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $256.35 | 2022-2023 | |
| Ucb, INC. | $224.75 | 2023-2025 | Briviact, Rystiggo, Fintepla |
| Genentech USA, INC. | $102.33 | 2024-2025 | Ocrevus, Ocrevus Zunovo |
| Celgene Corporation | $100.13 | 2023 | |
| Haemonetics Corporation | $90.09 | 2023 | Teg6s Hemostasis System |
| Abbvie INC. | $70.02 | 2023-2025 | Botox |
| Ceribell, INC. | $64.83 | 2023-2024 | Pocket Eeg Device, Ceribell Rapid Response Eeg |
| Alexion Pharmaceuticals, INC. | $46.91 | 2024 | Ultomiris |
| Livanova USA, INC. | $42.68 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Genzyme Corporation | $37.97 | 2024 | |
| Jazz Pharmaceuticals INC. | $33.76 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $27.31 | 2024 | Wainua |
| Eisai INC. | $25.56 | 2023 | |
| Immedica Pharma US, INC. | $24.71 | 2025 | Ztalmy |
| Alnylam Pharmaceuticals INC. | $21.19 | 2024 | Onpattro |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $20.73 | 2024 | Vyvgart, Vyvgart Hytrulo |
| Biogen, INC. | $19.77 | 2025 | Qalsody, Spinraza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Rubin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.